American Association of Immunologists (AAI) — Immunology Annual Meeting (IMMUNOLOGY2027™)

1) Event basics (from official source)

• Official event name: IMMUNOLOGY2027™ (110th annual meeting of AAI)
• Dates: April 30 to May 4
• Location (city): Los Angeles
• Country: United States (implied by Los Angeles, USA)
• Venue: Not specified in the provided official website text (left blank)
• Event positioning: “the leading annual all-immunology event worldwide”

This meeting is positioned as a global, all-immunology gathering under the American Association of Immunologists. The attendee and buyer mix typically includes immunology researchers, clinicians, academic leaders, translational scientists, industry scientists, and commercial teams supporting immunology R&D, diagnostics, therapeutics, and enabling technologies.

2) Who attends (buyers / attendees)

Because this is an all-immunology annual meeting, it is not limited to a single corporate procurement category. The audience generally spans multiple layers of the immunology ecosystem. For attendee-list targeting, we focus on “buyers” in the sense of decision-influencing stakeholders who actively evaluate, sponsor, procure, and partner around immunology work.

Primary attendee groups (high-value buyer profiles)

• Immunology and translational research leadership: principal investigators, lab directors, research program leaders, and departmental leadership who influence R&D priorities and budgets.
• Academic decision-makers: university administrators, research center directors, deans of research, and technology transfer leadership at academic institutions.
• Industry R&D decision-makers: immunology therapeutic area heads, discovery research managers, translational science leaders, and scientific program directors.
• Clinical and medical science leadership: medical affairs leaders, clinical operations leaders for immunology studies, and translational medicine contacts.
• Diagnostics and enabling technology stakeholders: teams that support immunoassays, biomarkers, flow cytometry, sequencing workflows, cell analysis, and related lab instrumentation and reagents.
• Commercial development / partnerships: business development leaders and partnering managers who pursue research collaborations, licensing, and ecosystem alliances.
• Supporting vendors and service providers: CROs, specialized research services, scientific tooling providers, and data/analytics providers with immunology-specific offerings.
• Conference exhibitors and sponsors: corporate representatives who attend to generate leads, validate interest with technical evaluators, and connect with research decision-makers.

3) Where the show is happening + attendee geographic origin

Show location

• City: Los Angeles
• Venue: Not specified in the provided official website text
• Country: United States

Attendee geographic origin

The official site describes the meeting as the “leading annual all-immunology event worldwide,” which strongly indicates international participation. However, the provided text does not include quantitative geographic breakdowns (e.g., % from North America vs. Europe vs. Asia-Pacific). Therefore, we characterize origin at the strategic level only:

• Primary likely origin: North America (given Los Angeles and AAI’s U.S. base)
• Significant international component: Europe, Asia-Pacific, and other global regions (consistent with “worldwide” positioning)
• Most important coverage goal for targeting: global immunology R&D and translational ecosystems, not only U.S.-based institutions

4) Audience reach (Local / National / Global)

Based on the official language (“leading annual all-immunology event worldwide”), the best fit for audience reach is:

• Reach type: Global
• Why: The meeting is explicitly positioned as a worldwide flagship immunology gathering.

5) Sample buyer company names (BUYERS ONLY) + websites

Below are buyer-style targets commonly relevant to all-immunology meetings (pharma/biotech, diagnostics, research tools, CROs, and enabling-technology providers). These are designed for outreach and buyer-enrichment workflows. If needed, we can refine the shortlist based on the client’s exact product category and use-cases.

Top buyer samples to send first (starter shortlist)

• Thermo Fisher Scientific
• BD (Becton, Dickinson and Company)
• Roche
• Novartis
• Pfizer

6) Job profiles, industries & event type

Event type

• Primary event type: Scientific conference / medical research meeting
• Core theme: All-immunology (research, translational science, clinical connections)
• Buyer implication: demand signals span research tools, diagnostics, therapeutics development, data/analytics, CRO services, and collaboration partnerships

Job profiles to target (buyer-oriented)

• Immunology Therapeutic Area Lead / Program Lead
• Director, Translational Medicine (Immunology)
• Head of Immunology Discovery / Research
• Director of Companion Diagnostics / Biomarker Strategy
• Medical Science Liaison Manager (Immunology)
• Scientific Director / VP R&D (Immunology)
• Director, Immunology Applications (for tool/reagent providers)
• Product Manager (Immunology workflows; sequencing/assays/instruments)
• Director of Immunology Research Services (CRO)
• Clinical Strategy Director / Immunology Clinical Operations leadership
• Technology Transfer Lead / Research Partnerships Director (academic-facing buyers)

Best-fit industries (mapped from provided industry list)

• Pharmaceuticals
• Biotechnology
• Medical Devices
• Health, Wellness & Fitness (when relevant to clinical research/medical science engagement)
• Hospital & Health Care (for academic medical centers and translational clinical stakeholders)
• Research
• Medical Practice (if targeting clinical/medical science roles)
• Information Technology & Services / Internet (only when client product is data/AI/analytics for immunology workflows)
• Professional Training & Coaching (only if the client product is training/compliance education specific to lab workflows; otherwise not primary)

7) Estimated attendance (expected total footfall)

Estimated attendance: Not stated in the provided official website text (left blank).

For planning purposes, we can estimate footfall only if the client provides either (a) the prior-year attendance, or (b) an exhibitor/sponsor prospectus that includes attendance numbers. If neither is available, we recommend capturing attendance indirectly (e.g., registration classes, exhibitor counts, session room count) during discovery.

8) Key focus areas & buyer engagement + client-product fit request

Key focus areas (what buyers are likely looking to engage on)

• Immunology research advancement: new findings across immunology subfields, including mechanistic and translational work.
• Translational science & biomarkers: moving from discovery to clinically actionable targets and immune readouts.
• Therapeutics development: immunology-driven discovery pipelines and development strategy discussions.
• Enabling technologies: tools, assays, lab workflows, and platforms that accelerate immunology experiments.
• Diagnostics and companion testing: immune markers and test strategies that support immunology trials and patient stratification.
• Partnerships and collaborations: research collaborations, licensing conversations, and vendor evaluation in technical sessions and exhibits.

Buyer engagement approach (how to position outreach)

Since the meeting is “all-immunology” and globally oriented, the most effective buyer engagement angle is rarely “generic immunology interest.” Instead, it should connect to a specific immunology workflow:

• Discovery workflow enablement: target roles focused on immunology discovery outputs and assay readiness.
• Translational biomarker strategy: target roles focused on biomarkers, companion diagnostics, and translational readouts.
• Clinical readiness: target medical science and translational/clinical strategy stakeholders.
• Laboratory operational efficiency: for enabling tech, connect to throughput, reproducibility, or instrumentation adoption.

Client-product fit request (required to refine “best buyers”)

We can generate the best buyer subset for this event only after we review the client product positioning. Please share the client product website (URL) so We can review it and identify which immunology buyer segments are the strongest matches (e.g., therapeutics R&D vs diagnostics vs lab tools vs CRO services vs data platforms).

Once the website is provided, We will return:

• The best buyer company types to prioritize (with justification)
• The highest-likelihood job titles/titles to target
• The most relevant industry filters (from your provided industry list)
• A refined shortlist inside the broader table above (so the final outreach list stays tightly aligned)

9) Final recommendation (event suitability)

Overall fit: High—because the meeting is explicitly positioned as the “leading annual all-immunology event worldwide.” Buyer relevance is strong for immunology R&D leadership, translational science, immunology diagnostics/biomarkers, research tools, CRO services, and scientific enablement providers.

• Best for: companies with immunology-adjacent products, services, platforms, or partner programs
• Best buyer density expectation: moderate-to-high in exhibitors/sponsors and technical decision roles
• Primary targeting strategy: focus on immunology workflow owners (discovery, translational, biomarkers/diagnostics, clinical strategy, and enabling technologies)

Quick summary

• When: April 30 to May 4
• Where: Los Angeles, United States (venue not specified in provided text)
• Reach: Global (“leading annual all-immunology event worldwide”)
• Buyer segments: immunology therapeutic R&D, translational/biomarkers, diagnostics/cDx, lab tools/workflows, CRO and research services, partnerships
• Next step for “best buyers”: share the client website URL for product-fit review